Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on EquityReturn on Sales

Prelude Therapeutics (PRLD) Return on Sales (2024 - 2025)

Historic Return on Sales for Prelude Therapeutics (PRLD) over the last 2 years, with Q3 2025 value amounting to 3.14%.

  • Prelude Therapeutics' Return on Sales rose 83200.0% to 3.14% in Q3 2025 from the same period last year, while for Sep 2025 it was 5.17%, marking a year-over-year change of. This contributed to the annual value of 19.96% for FY2024, which is N/A changed from last year.
  • Per Prelude Therapeutics' latest filing, its Return on Sales stood at 3.14% for Q3 2025, which was up 83200.0% from 9.74% recorded in Q2 2025.
  • Over the past 5 years, Prelude Therapeutics' Return on Sales peaked at 3.14% during Q3 2025, and registered a low of 11.46% during Q3 2024.